Tags : TetraGenetics

Biotech

Imbrium Signs a License Agreement with TetraGenetics for its TetraExpress

Shots: TetraGenetics to receive $25M upfront, $248M milestones as contingent payments, FTE payments and royalties upto 7% on sales of product. Imbrium to get license for TetraGenetics’ TetraExpress Technology with an option to develop therapies post IND submission for pain and autoimmune disorders The focus of the agreement is to develop non-opioid therapies with advancement […]Read More